[1] Beitelshees A L, Horenstein R B, Vesely M R, et al. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions[J].Clin Pharmacol Ther,2011,89(3):455-459.
[2] Gurbel P A, Tantry U S, Shuldiner A R, et al. Genotyping: one piece of the puzzle to personalize antiplatelet therapy[J].J Am Coll Cardiol,2010,56(2):112-116.
[3] Shuldiner A R, O’Connell J R, Bliden K P, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009,302(8):849-857.
[4] Zhou S F, Liu J P, Chowbay B, et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact[J].Drug Metab Rev,2009,41(2):89-295.
[5] Djaffar Jureidini I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population[J].Mol Biol Rep,2011,38(8):5449-5452
[6] Yin S J, Ni Y B, Wang S M, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations[J].J Clin Pharm Ther,2012,37(3):364-369.
[7] Shi Y, Xiang P, Li L, et al. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population[J].Forensic Sci Int,2011,207(1-3):183-187.
[8] Tang X F, Wang J, Zhang J H, et al. Effect of the cyp2c19 2 and 3 genotypes, abcb1 c3435t and pon1 q192r alleles on the pharmacodynamics and adverse clinical events of clopidogrel in chinese people after percutaneous coronary intervention[J].Eur J Clin Pharmacol,2013,69(5):1103-1112.
[9] 周 健,吕 虹,康熙雄,等.药物代谢酶CYP2D6和CYP2C19的基因多态性与个体化治疗[J].中国医药生物技术,2009,4(4):299-302.
[10] 韩雅玲.冠心病抗血小板治疗[J]. 武警医学,2006,17(3):163-166.
[11] Jeong Y H, Tantry U S, Kim I S,et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin[J].Circ Cardiovasc Interv,2011,4(6):585-594.
[12] Hou X, Shi J, Sun H,et al. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis[J].Eur J Clin Pharmacol,2014,70(9):1041-1047.
[13] Shalia K K, Shah V K, Pawar P,et al. Polymorphisms of mdr1, cyp2c19 and p2y12 genes in indian population: effects on clopidogrel response[J].Indian Heart J,2013,65(2):158-167.
[14] Zhang L, Chen Y, Jin Y,et al. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated chinese patients[J].Thromb Res,2013,132(1):81-87.
[15] Collet J P, Hulot J S, Anzaha G,et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)[J].JACC Cardiovasc Interv,2011,4(4):392-402.
[16] Mega J L, Hochholzer W, Frelinger A L,et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J].JAMA,2011,306(20):2221-2228.
[17] Montalescot G, Wiviott S D, Braunwald E,et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial[J].Lancet,2009,373(9665):723-731.
[18] Li L, Li H Y, Qiao R,et al. Predictive value of antiplatelet resistance on early stent thrombosis in patients with acute coronary syndrome[J].Chin Med J (Engl),2013,126(4):626-633.
[19] Wang Z J, Zhou Y J, Liu Y Y,et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent[J].Thromb Res,2009,124(1):46-51.
[20] Simon T, Verstuyft C, Mary-Krause M,et al. Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med,2009,360(4):363-375.
[21] Collet J P, Hulot J S, Pena A,et al.Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study[J].Lancet,2009,373(9660):309-317.
[22] Sibbing D, Stegherr J, Latz W,et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J].Eur Heart J,2009,30(8):916-922.
[23] Mao L, Jian C, Changzhi L,et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects[J].Arch Cardiovasc Dis,2013,106(10):517-527.
[24] Tang X F, He C, Yuan J Q,et al. Impact of cytochrome p450 2c19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated chinese patients after percutaneous coronary intervention [J].Zhonghua Xin Xue Guan Bing Za Zhi,2011,39(7):617-620.
[25] Kim H S, Cho D Y, Park B M,et al. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration[J].J Clin Pharmacol,2014,54(8):850-857.
[26] Pare G, Mehta S R, Yusuf S,et al. Effects of cyp2c19 genotype on outcomes of clopidogrel treatment[J].N Engl J Med,2010,363(18):1704-1714.
[27] Park J, Shin D H, Kim B K,et al. Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation[J].Eur Heart J Cardiovasc Imaging,2013,14(12):1181-1186.
[28] Bauer T, Bouman H J, Van Werkum J W,et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis[J].BMJ,2011,343(1):d4588.
[29] Peng Y, Chen M, Liu X J,et al. The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease[J].Atherosclerosis,2013,227(1):106-111.
[30] Lev E I, Patel R T, Maresh K J,et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance[J].J Am Coll Cardiol,2006,47(1):27-33.
[31] Armstrong P C, Dhanji A R, Tucker A T,et al. Reduction of platelet thromboxane a2 production ex vivo and in vivo by clopidogrel therapy[J]. Thromb Haemost,2010,8(3):613-615.
[32] Ivandic B T, Sausemuth M, Ibrahim H,et al. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention[J].Clin Chem,2009,55(6):1171-1176.